Monte Rosa Therapeutics, Inc. (GLUE) — Financial statements
Income statement, balance sheet, and cash flow for Monte Rosa Therapeutics, Inc. — annual and quarterly history with growth and margin analysis.
| Metric (USD Millions) | 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|---|
| Revenue & Gross Profit | ||||||
| Revenue | 124↑63.5% | 76 | 0.00 | 0.00 | 0.00 | |
| Cost of Revenue | 8↑2.9% | 8↑30.5% | 6 | 0.00 | 0.00 | |
| Gross Profit | 115↑70.8% | 68↑1184.9% | -6 | 0.00 | 0.00 | |
| Operating Expenses | ||||||
| R&D Expenses | 142↑16.4% | 122↑15.7% | 105↑23.5% | 85↑48.8% | 57 | |
| General & Administrative Expenses | 36↑3.4% | 35↑9.8% | 32↑17.3% | 27↑73.7% | 16 | |
| Selling & Marketing Expenses | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| SG&A Expenses | 36↑3.4% | 35↑9.8% | 32↑17.3% | 27↑73.7% | 16 | |
| Other Expenses | -8↓2.9% | -8 | 0.00 | 0.00 | 0.00 | |
| Operating Expenses | 170↑14.1% | 149↑8.4% | 137↑22.0% | 112↑54.2% | 73 | |
| Total Costs & Expenses | 178↑13.5% | 157↑9.4% | 143↑27.5% | 112↑54.2% | 73 | |
| Operating Results | ||||||
| Operating Income | -54↑33.2% | -81↑43.4% | -143↓27.5% | -112↓54.2% | -73 | |
| Depreciation & Amortization | 8↑2.9% | 8↑30.5% | 6↑66.1% | 4↑75.7% | 2 | |
| EBITDA | -46↑37.2% | -73↑46.8% | -137↓26.2% | -109↓53.6% | -71 | |
| EBIT | -54↑33.2% | -81↑43.4% | -143↓27.5% | -112↓54.2% | -73 | |
| Interest & Other Income | ||||||
| Net Interest Income | 13↑22.5% | 11↑13.2% | 9 | 0.00↓100.0% | 0.05 | |
| Interest Income | 13↑22.5% | 11↑13.2% | 9↑148.0% | 4↑8082.6% | 0.05 | |
| Interest Expense | 0.00 | 0.00 | 0.00↓100.0% | 4 | 0.00 | |
| Non-Operating Income | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Other Income / Expenses | 14↑31.9% | 11↑32.4% | 8↑113.7% | 4↑460.9% | -1 | |
| Income Before Tax | -40↑43.4% | -70↑48.1% | -135↓24.4% | -109↓46.7% | -74 | |
| Income Tax Expense | -1↓142.7% | 3↑660.4% | 0.34 | 0.00 | 0.00 | |
| Net Income & EPS | ||||||
| Net Income from Continuing Operations | -39↑46.9% | -73↑46.3% | -135↓24.7% | -109↓46.7% | -74 | |
| Net Income from Discontinued Operations | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Net Income | -39↑46.9% | -73↑46.3% | -135↓24.7% | -109↓46.7% | -74 | |
| Bottom-Line Net Income | -39↑46.9% | -73↑46.3% | -135↓24.7% | -109↓46.7% | -74 | |
| EPS (Basic) | -0.46↑53.1% | -0.98↑62.7% | -2.63↓14.3% | -2.30↓44.7% | -1.59 | |
| EPS (Diluted) | -0.46↑53.1% | -0.98↑62.7% | -2.63↓14.3% | -2.30↓44.7% | -1.59 | |
| Weighted Average Shares | 83↑12.4% | 74↑43.8% | 51↑8.8% | 47↑1.5% | 47 | |
| Weighted Average Diluted Shares | 83↑12.4% | 74↑43.8% | 51↑8.8% | 47↑1.5% | 47 | |
* All figures in Millions of USD, except per share data. Growth rates calculated Year-over-Year (YoY). Data source: SEC Filings.